LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 67

Search options

  1. Article: Die Wehrkonzeption und ihre Praktizierung durch Helmut Schmidt

    Reichel, Karl Hubert / Schmidt, Helmut

    Marxistische Blätter Vol. 8, No. 4 , p. 24-28

    1970  Volume 8, Issue 4, Page(s) 24–28

    Author's details Karl Hubert Reichel
    Keywords Wehrpolitik ; Deutschland
    Language German
    Publisher Neue Impulse Verl.
    Publishing place Essen
    Document type Article
    ZDB-ID 1142-3
    Database ECONomics Information System

    More links

    Kategorien

  2. Book ; Thesis: Quantitativer Nachweis von 1,25-Dihydroxy-Vitamin [Dihydroxy-Vitamin] D3 [D] im Serum des Menschen

    Reichel, Helmut

    Unters. zu e. spezif. u. sensitiven Sättigungsanalyse u. Weiterentwicklung d. Tritiummesstechnik

    1983  

    Title variant Quantitativer Nachweis von 1,25-Dihydroxy-Vitamin D3 im Serum des Menschen
    Size 169 Bl. : graph. Darst.
    Document type Book ; Thesis
    Thesis / German Habilitation thesis Heidelberg, Univ., Diss., 1984
    HBZ-ID HT003258732
    Database Catalogue ZB MED Medicine, Health

    Kategorien

  3. Article ; Online: Low-dose alfacalcidol controls secondary hyperparathyroidism in predialysis chronic kidney disease.

    Reichel, Helmut

    Nephron. Clinical practice

    2010  Volume 114, Issue 4, Page(s) c268–76

    Abstract: In the long term, secondary hyperparathyroidism (sHPT) causes severe osseous and non-osseous problems in patients with chronic kidney disease (CKD). Active vitamin D metabolites, i.e. calcitriol and alfacalcidol, have been utilized for sHPT treatment for ...

    Abstract In the long term, secondary hyperparathyroidism (sHPT) causes severe osseous and non-osseous problems in patients with chronic kidney disease (CKD). Active vitamin D metabolites, i.e. calcitriol and alfacalcidol, have been utilized for sHPT treatment for more than 20 years. Yet, data on predialysis CKD patients are rather sparse. We monitored alfacalcidol therapy in 1,159 patients with CKD and sHPT in a 12-month multicenter observational study. Virtually all patients were in CKD stages 3-5 at study begin. The patients were recruited from 241 German nephrological centers. The mean alfacalcidol dose at study begin was 0.28 microg per day and 61.8% of patients received alfacalcidol daily (mean dose 0.34 microg); the remainder of the patients received intermittent therapy (mostly 3 times weekly, mean dose 0.19 microg/day). The initial alfacalcidol dose was maintained in 67.5% of patients; it was increased in 22% and decreased in 10.6%. At study end, the mean alfacalcidol dose was 0.32 microg/day. The mean calculated glomerular filtration rate decreased by 2.8 ml/min during the study (p < 0.001). The mean parathyroid hormone (PTH) concentration decreased from 27.5 to 23.1 pmol/l (p < 0.01) in the whole patient group. In the subgroup with intact PTH (iPTH) >20 pmol/l (48.3% of patients), the mean iPTH decreased from 41.3 to 30.9 pmol/l (p < 0.001). In the subgroups with iPTH <20 pmol/l at study begin, iPTH remained constant. The mean serum calcium increased from 2.23 to 2.31 mmol/l (p < 0.001) and 7.7% of patients had at least one serum calcium value above the normal range. Serum phosphate increased from 1.50 to 1.57 mmol/l (p < 0.001) and phosphate rose above 1.8 mmol/l in 21.5% of patients. Serum calcitriol increased significantly from 20.6 ng/l at baseline to 31.1 ng/l during the last quarter of the study (p < 0.001). iPTH was correlated negatively with kidney function, serum calcium and calcitriol and positively with serum phosphate. The frequency of side effects attributed to alfacalcidol was very low. Taken together, low-dose alfacalcidol prevented progression or caused regression of sHPT in a large cohort of CKD 3-5 patients. There were little effects on serum calcium and phosphate. Due to non-calciotropic activities of calcitriol, the alfacalcidol-induced rise in serum calcitriol could be clinically beneficial. The data support the concept that sHPT should be treated rather early in the course of CKD.
    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Calcium/blood ; Drug Administration Schedule ; Female ; Humans ; Hydroxycholecalciferols/administration & dosage ; Hydroxycholecalciferols/therapeutic use ; Hyperparathyroidism, Secondary/blood ; Hyperparathyroidism, Secondary/drug therapy ; Hyperparathyroidism, Secondary/etiology ; Kidney Failure, Chronic/blood ; Kidney Failure, Chronic/complications ; Kidney Failure, Chronic/drug therapy ; Kidney Function Tests/methods ; Male ; Middle Aged ; Prospective Studies ; Renal Dialysis ; Young Adult
    Chemical Substances Hydroxycholecalciferols ; Calcium (SY7Q814VUP) ; alfacalcidol (URQ2517572)
    Language English
    Publishing date 2010
    Publishing country Switzerland
    Document type Comparative Study ; Journal Article ; Multicenter Study
    ZDB-ID 207121-6
    ISSN 1660-2110 ; 1423-0186 ; 2235-3186 ; 1660-8151 ; 0028-2766
    ISSN (online) 1660-2110 ; 1423-0186 ; 2235-3186
    ISSN 1660-8151 ; 0028-2766
    DOI 10.1159/000276579
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Economic burden of secondary hyperparathyroidism in Germany: a matched comparison.

    Reichel, Helmut / Seibert, Eric / Tillmann, Frank-Peter / Barck, Isabella / Grava, Astride / Schneider, Kim Maren / Meise, Dominic

    International urology and nephrology

    2022  Volume 55, Issue 5, Page(s) 1291–1300

    Abstract: Purpose: Secondary hyperparathyroidism (SHPT) of renal origin is a progressive complication in chronic kidney disease (CKD) and is associated with serious osseous and non-osseous complications, CKD progression, and economic burden for healthcare systems ...

    Abstract Purpose: Secondary hyperparathyroidism (SHPT) of renal origin is a progressive complication in chronic kidney disease (CKD) and is associated with serious osseous and non-osseous complications, CKD progression, and economic burden for healthcare systems worldwide. We aimed at assessing characteristics, healthcare resource utilization, and costs of incident SHPT patients in CKD stage 3 (CKD3) and 4 (CKD4), using administrative claims data.
    Methods: German claims data were used to identify CKD3 and CKD4 patients, who were stratified by the occurrence of incident SHPT. Patients with SHPT were matched 1:1 to non-SHPT patients with the same CKD stage using propensity scores. Matched groups were compared during a 2-year follow-up period.
    Results: Overall, 1156 CKD3 and 517 CKD4 incident SHPT patients and their respective matches were identified. Mean number of all-cause hospitalizations were significantly higher among SHPT patients (2.7 vs. 2.0 in CKD3, 2.8 vs. 1.5 in CKD4) during follow-up. Similarly, the mean number of outpatient encounters was significantly higher among the SHPT cohorts (95.0 vs. 64.3 in CKD3, 101.4 vs. 49.8 in CKD4). SHPT patients progressed to CKD5 more often (6.1% vs. 1.2% from CKD3, 26.7% vs. 2.9% from CKD4, both P < 0.01) resulting in a higher proportion of dialysis (6.1% vs. 1.3% in CKD3, 22.1% vs. 3.7% in CKD4, both P < 0.01). Consequently, average all-cause healthcare costs significantly increased per patient (€19,477 vs. €15,115 in CKD3, €25,921 vs. €12,265 in CKD4).
    Conclusions: Patients with CKD3&4 and incident SHPT of renal origin presented with significantly higher healthcare resource utilization and costs, as well as increased disease progression compared to non-SHPT patients.
    MeSH term(s) Humans ; Financial Stress ; Kidney ; Renal Insufficiency, Chronic/epidemiology ; Renal Insufficiency, Chronic/therapy ; Renal Insufficiency, Chronic/complications ; Hyperparathyroidism, Secondary/epidemiology ; Hyperparathyroidism, Secondary/etiology ; Germany/epidemiology
    Language English
    Publishing date 2022-12-08
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 204048-7
    ISSN 1573-2584 ; 0301-1623 ; 0042-1162
    ISSN (online) 1573-2584
    ISSN 0301-1623 ; 0042-1162
    DOI 10.1007/s11255-022-03425-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: International practice patterns of dyslipidemia management in patients with chronic kidney disease under nephrology care: is it time to review guideline recommendations?

    Calice-Silva, Viviane / Muenz, Daniel / Wong, Michelle M Y / McCullough, Keith / Charytan, David / Reichel, Helmut / Robinson, Bruce / Stengel, Benedicte / Massy, Ziad A / Pecoits-Filho, Roberto

    Lipids in health and disease

    2023  Volume 22, Issue 1, Page(s) 67

    Abstract: Background: In contrast to guidelines related to lipid therapy in other areas, 2012 Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommend conducting a lipid profile upon diagnosis of chronic kidney disease (CKD) and treating all patients ...

    Abstract Background: In contrast to guidelines related to lipid therapy in other areas, 2012 Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommend conducting a lipid profile upon diagnosis of chronic kidney disease (CKD) and treating all patients older than 50 years without defining a target for lipid levels. We evaluated multinational practice patterns for lipid management in patients with advanced CKD under nephrology care.
    Methods: We analyzed lipid-lowering therapy (LLT), LDL- cholesterol (LDL-C) levels, and nephrologist-specified LDL-C goal upper limits in adult patients with eGFR < 60 ml/min from nephrology clinics in Brazil, France, Germany, and the United States (2014-2019). Models were adjusted for CKD stage, country, cardiovascular risk indicators, sex, and age.
    Results: LLT treatment differed significantly by country, from 51% in Germany to 61% in the US and France (p = 0.002) for statin monotherapy. For ezetimibe with or without statins, the prevalence was 0.3% in Brazil to 9% in France (< 0.001). Compared with patients not taking lipid-lowering therapy, LDL-C was lower among treated patients (p < 0.0001) and differed significantly by country (p < 0.0001). At the patient level, the LDL-C levels and statin prescription did not vary significantly by CKD stage (p = 0.09 LDL-C and p = 0.24 statin use). Between 7-23% of untreated patients in each country had LDL-C ≥ 160 mg/dL. Only 7-17% of nephrologists believed that LDL-C should be < 70 mg/dL.
    Conclusion: There is substantial variation in practice patterns regarding LLT across countries but not across CKD stages. Treated patients appear to benefit from LDL-C lowering, yet a significant proportion of hyperlipidemia patients under nephrologist care are not receiving treatment.
    MeSH term(s) Adult ; Humans ; United States ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Cholesterol, LDL ; Nephrology ; Dyslipidemias/epidemiology ; Renal Insufficiency, Chronic/drug therapy ; Treatment Outcome
    Chemical Substances Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Cholesterol, LDL
    Language English
    Publishing date 2023-05-25
    Publishing country England
    Document type Journal Article
    ZDB-ID 2091381-3
    ISSN 1476-511X ; 1476-511X
    ISSN (online) 1476-511X
    ISSN 1476-511X
    DOI 10.1186/s12944-023-01833-z
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Antikoagulation bei Patienten mit Niereninsuffizienz

    Reichel, Helmut

    Thromboembolie im Fokus

    2009  Volume -, Issue 1, Page(s) 10

    Language German
    Document type Article
    ZDB-ID 2388845-3
    ISSN 1865-1437
    Database Current Contents Medicine

    More links

    Kategorien

  7. Article: Differenzialdiagnose der Hypercalcämie

    Reichel, Helmut

    Nephrologie im Dialog

    2009  Volume -, Issue 3, Page(s) 16

    Language German
    Document type Article
    ZDB-ID 2085327-0
    ISSN 1618-4319
    Database Current Contents Medicine

    More links

    Kategorien

  8. Article: Current treatment options in secondary renal hyperparathyroidism.

    Reichel, Helmut

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

    2006  Volume 21, Issue 1, Page(s) 23–28

    MeSH term(s) Calcitriol/therapeutic use ; Calcium Channel Agonists/therapeutic use ; Drug Therapy, Combination ; Female ; Follow-Up Studies ; Humans ; Hyperparathyroidism, Secondary/drug therapy ; Hyperparathyroidism, Secondary/epidemiology ; Hyperparathyroidism, Secondary/etiology ; Incidence ; Kidney Failure, Chronic/complications ; Kidney Function Tests ; Male ; Parathyroid Hormone/metabolism ; Risk Assessment ; Severity of Illness Index ; Treatment Outcome ; Vitamin D/therapeutic use
    Chemical Substances Calcium Channel Agonists ; Parathyroid Hormone ; Vitamin D (1406-16-2) ; Calcitriol (FXC9231JVH)
    Language English
    Publishing date 2006-01
    Publishing country England
    Document type Comparative Study ; Journal Article ; Review
    ZDB-ID 90594-x
    ISSN 1460-2385 ; 0931-0509
    ISSN (online) 1460-2385
    ISSN 0931-0509
    DOI 10.1093/ndt/gfi097
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Erhöhtes Calcium als Zufallsbefund.

    Reichel, Helmut

    Medizinische Klinik (Munich, Germany : 1983)

    2005  Volume 100, Issue 8, Page(s) 486–94; quiz 495–6

    Title translation Increased calcium as accidental finding.
    MeSH term(s) Adenoma/complications ; Adenoma/diagnosis ; Adenoma/surgery ; Adult ; Age Factors ; Calcium/blood ; Diagnosis, Differential ; Emergencies ; Female ; Humans ; Hypercalcemia/blood ; Hypercalcemia/diagnosis ; Hypercalcemia/drug therapy ; Hypercalcemia/epidemiology ; Hypercalcemia/etiology ; Hypercalcemia/therapy ; Lymphoma, Non-Hodgkin/complications ; Lymphoma, Non-Hodgkin/diagnosis ; Male ; Middle Aged ; Parathyroid Hormone/blood ; Parathyroid Neoplasms/complications ; Parathyroid Neoplasms/diagnosis ; Parathyroid Neoplasms/surgery ; Parathyroidectomy ; Sex Factors
    Chemical Substances Parathyroid Hormone ; Calcium (SY7Q814VUP)
    Language German
    Publishing date 2005-08-15
    Publishing country Germany
    Document type Case Reports ; Comparative Study ; Journal Article ; Review
    ZDB-ID 3232-3
    ISSN 1615-6722 ; 0723-5003 ; 0025-8458 ; 0724-3758 ; 0931-7171
    ISSN (online) 1615-6722
    ISSN 0723-5003 ; 0025-8458 ; 0724-3758 ; 0931-7171
    DOI 10.1007/s00063-005-1062-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: Literatur. Effekte der Vitamin-D-Metaboliten

    Reichel, Helmut

    Nephrologie im Dialog

    2008  Volume -, Issue 3, Page(s) 14

    Language German
    Document type Article
    ZDB-ID 2085327-0
    ISSN 1618-4319
    Database Current Contents Medicine

    More links

    Kategorien

To top